PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于树突状细胞的治疗性肿瘤疫苗的研究进展
英文原题：Advances in dendritic cell-based therapeutic tumor vaccines.
查看英文原题
Advances in dendritic cell-based therapeutic tumor vaccines.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
基于树突状细胞的治疗性肿瘤疫苗是一种在临床上常被尝试的主动免疫疗法，恶性肿瘤的传统治疗手段如手术、放疗和化疗，存在复发率高和副作用大的缺点。树突状细胞疫苗通过患者自身的免疫系统来破坏肿瘤细胞，是一种非常有前景的治疗方法。然而，由于肿瘤免疫微环境的抑制、最佳特异性抗原筛选的困难以及疫苗生产的技术难度高。目前临床上可用的大多数肿瘤疫苗未能产生显著的临床治疗效果。在这篇综述中，简要概述了治疗性树突状细胞疫苗疗法的基本原理，重点介绍了临床上治疗性树突状细胞疫苗研究的进展以及为增强树突状细胞疫苗抗肿瘤效果所采取的举措。相信通过不断探索新的治疗策略，治疗性树突状细胞疫苗可以在改善肿瘤患者的肿瘤治疗中发挥更大的作用。
展开英文摘要原文
Dendritic cell-based therapeutic tumor vaccines are an active immunotherapy that has been commonly tried in the clinic,traditional treatment modalities for malignant tumors, such as surgery, radiotherapy and chemotherapy, have the disadvantages of high recurrence rates and side effects. The dendritic cell vaccination destroys cells from tumors by means of the patient's own system of immunity, a very promising treatment.
However, due to the suppression of the tumor immune microenvironment, the difficulty of screening for optimal specific antigens, and the high technical difficulty of vaccine production. Most tumor vaccines currently available in the clinic have failed to produce significant clinical therapeutic effects.
In this review, the fundamentals of therapeutic dendritic cells vaccine therapy are briefly outlined, with a focus on the progress of therapeutic Dendritic cells vaccine research in the clinic and the initiatives undertaken to enhance dendritic cell vaccinations' anti-tumor effectiveness. It is believed that through the continuous exploration of novel therapeutic strategies, therapeutic dendritic cells vaccines can play a greater role in improving tumor treatment for tumor patients.
论文信息
- 作者
- Qin S、Na J、Yang Q、Tang J、Deng Y、Zhong L
- 第一作者单位
- State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Therangstics, Guangxi Key Laboratory of Bio-targeting Therangstics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Guangxi Medical University, Nanning 530021, China. Electronic address: 18897732593@163.com.China
- 通讯作者单位
- State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Therangstics, Guangxi Key Laboratory of Bio-targeting Therangstics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Guangxi Medical University, Nanning 530021, China; Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi 530021, China. Electronic address: zhongliping@gxmu.edu.cn.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Molecular immunology2025 May
- 原文标识
- PubMed 40120558 · DOI 10.1016/j.molimm.2025.03.005